Esperion Therapeutics (ESPR) Cash from Operations Growth (1y) (2013 - 2026)
Esperion Therapeutics (ESPR) Cash from Operations Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 61.90% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -22.14% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 0.46% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 125.00% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 425.00% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -267.74% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -18.09% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 16.33% |
| 10 | Esperion Therapeutics | 49.69 Mn | -118.16 Mn | 45.53 Mn | -22.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.51% |
| Dec 31, 2025 | 229.44% |
| Sep 30, 2025 | 87.87% |
| Jun 30, 2025 | -336.11% |
| Mar 31, 2025 | -142.04% |
| Dec 31, 2024 | 5.68% |
| Sep 30, 2024 | -82.79% |
| Jun 30, 2024 | 70.89% |
| Mar 31, 2024 | 199.03% |
| Dec 31, 2023 | 12.75% |
| Sep 30, 2023 | 54.88% |
| Jun 30, 2023 | 51.02% |
| Mar 31, 2023 | -39.41% |
| Dec 31, 2022 | 26.40% |
| Sep 30, 2022 | 38.07% |
| Jun 30, 2022 | -5.57% |
| Mar 31, 2022 | 56.22% |
| Dec 31, 2021 | 15.82% |
| Sep 30, 2021 | 20.19% |
| Jun 30, 2021 | -134.34% |